MBIO Insider Trading

Insider Ownership Percentage: 0.21%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Mustang Bio Insider Trading History Chart

This chart shows the insider buying and selling history at Mustang Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$2k$0$2kTotal Insider BuyingTotal Insider Selling

Mustang Bio Share Price & Price History

Current Price: $1.16
Price Change: Price Decrease of -0.005 (-0.43%)
As of 04/29/2025 11:30 AM ET

This chart shows the closing price history over time for MBIO up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarApr$1.16Closing price on 04/28/25:

Mustang Bio Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Mustang Bio (NASDAQ:MBIO)

9.95% of Mustang Bio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at MBIO by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$45kbought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1M$0$1MTotal InflowsTotal Outflows
Mustang Bio logo
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
Read More on Mustang Bio

Today's Range

Now: $1.16
Low: $1.13
High: $1.18

50 Day Range

MA: $1.57
Low: $1.16
High: $2.93

52 Week Range

Now: $1.16
Low: $1.12
High: $65.00

Volume

48,745 shs

Average Volume

325,946 shs

Market Capitalization

$3.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.14